| Drug Type TCR-T Cell therapy | 
| Synonyms GB3007 NY-ESO1 TCRT, GB 3007, GB-3007 | 
| Target | 
| Action inhibitors | 
| Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), T lymphocyte replacements | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Multiple Myeloma | Preclinical | China  | - | |
| Synovial Sarcoma | Discovery | China  | 30 Jan 2022 | 





